A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study of CK-2127107 in Two Ascending Dose Cohorts of Patients With Spinal Muscular Atrophy (SMA)
Phase of Trial: Phase II
Latest Information Update: 29 Aug 2017
At a glance
- Drugs CK 2127107 (Primary)
- Indications Spinal muscular atrophy
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Cytokinetics
- 17 Aug 2017 Planned End Date changed from 1 Dec 2016 to 1 Feb 2018.
- 17 Aug 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2018.
- 02 Aug 2017 According to a Cytokinetics media release, the company expects data from this study in 1Q of 2018.